REFERENCES
- Calafat A., Bohn K., Juan M., Kokkevi A., Maalsté N., Mendes F., Sureda P., Simon J., Stocco P., van de Wijngaart G. Conclusions and recommendations. Night life in Europe and recreative drug use1st. Martin impressores, S. L. Palma de Mallorca. 1999, Sonar 98
- Pope H G., Jr., Ionescu-Pioggia M., Pope K. W. Drug use and life style among college undergraduates: a 30-year longitudinal study. Am. J. Psychiatry 2001; 158(9)1519–1521, [PUBMED], [INFOTRIEVE]
- Strote J., Lee J. E., Wechsler H. Increasing MDMA use among college students: results of a national survey. J. Adolesc. Health 2002; 30(1)64–72, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wilkins C., Bhatta K., Pledger M., Casswell S. Ecstasy use in New Zealand: findings from the 1998 and 2001 National Drug Surveys. N. Z. Med. J. 2003; 116(1171)U383, [PUBMED], [INFOTRIEVE]
- Ahmad K. Increased use of amphetamine-type stimulants threatens east Asian countries. Lancet 2002; 359(9321)1927, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Palomino E. A Cena Techono. Babado forte: moda, música e noite na virada do século 211st. São Paulo, Mandarim. 1999; 88–89
- Spielberger C. D., Gorsuch R. L., Lushene R. E. Descrição, Aplicação, Avaliação. Inventário de Ansiedade Traço-Estado IDATE1st. CEPA, Rio de Janeiro. 1979; 3–12
- Gorenstein C., Pompeia S., Andrade L. Scores of Brazilian University students on the Beck Depression and the State Trait Anxiety Inventories. Psychol. Rep. 1995; 77(2)635–641, [PUBMED], [INFOTRIEVE], [CSA]
- Tavares H. Jogo patológico e suas relações com o espectro impulsivo-compulsivo. Universidade de São Paulo, São Paulo. 2000
- Zemishlany Z., Aizenberg D., Weizman A. Subjective effects of MDMA (‘Ecstasy’) on human sexual function. Eur. Psychiatry 2001; 16(2)127–130, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pedersen W., Skrondal A. Ecstasy and new patterns of drug use: a normal population study. Addiction 1999; 94(11)1695–1706, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Schuster P., Lieb R., Lamertz C., Wittchen H. U. Is the use of ecstasy and hallucinogens increasing? Results from a community study. Eur. Addict. Res. 1998; 4(1–2)75–82, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tossmann P., Boldt S., Tensil M. D. The use of drugs within the techno party scene in European metropolitan cities. Eur. Addict. Res. 2001; 7(1)2–23, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Calafat A., Stocco P., Mendes F., Kokkevi A., Maalsté N, Mendes F, Sureda P., Simon J., Stocco P., van de Wijngaart G. Characteristics and social representation of ecstasy in Europe1st. Martin impressores, S.L., Valencia. 1998
- Boot B. P., McGregor I. S., Hall W. MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 2000; 355(9217)1818–1821, [PUBMED], [INFOTRIEVE], [CROSSREF]
- McGuire P. K., Cope H., Fahy T. A. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine (‘Ecstasy’). British Journal of Psychiatry 1994; 165(3)391–395, [PUBMED], [INFOTRIEVE]
- Cohen R. S. Subjective reports on the effects of the MDMA (‘ecstasy’) experience in humans. Progress in. Neuro-Psychopharmacology & Biological Psychiatry 1995; 19(7)1137–114, [CROSSREF]
- Gamma A., Frei E., Lehmann D., Pascual-Marqui R. D., Hell D., Vollenweider F. X. Mood state and brain electric activity in ecstasy users. Neuroreport 2000; 11(1)157–16, [PUBMED], [INFOTRIEVE], [CSA]
- Wareing M., Fisk J. E., Murphy P. N. Working memory deficits in current and previous users of MDMA (‘ecstasy’). Br. J. Psychol. 2000; 91: 181–188, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Parrott A. C. Human research on MDMA (3,4-methylene-dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 2000; 42(1)17–24, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Morgan M. J., McFie L., Fleetwood H., Robinson J. A. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?. Psychopharmacology (Berl) 2002; 159(3)294–303, [CSA], [CROSSREF]
- MacInnes N., Handley S. L.Harding G. F. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J. Psychopharmacol. 2001; 15(3)181–186, [PUBMED], [INFOTRIEVE], [CSA]
- Kish S. J. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?. Pharmacol. Biochem. Behav. 2002; 71(4)845–855, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cole J. C., Sumnall H. R. Altered states: the clinical effects of Ecstasy. Pharmacol. Ther. 2003; 98(1)35–58, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Nappo S. A., Galduroz J. C., Noto A. R. Crack use in São Paulo. Substance Use Misuse 1996; 31(5)565–579, [PUBMED], [INFOTRIEVE], [CSA]